Collecting Biomarkers in Pancreatic Cancer

This study is collecting blood samples from people with pancreatic cancer to help future research. We are looking for volunteers who have a known or presumed diagnosis of pancreatic adenocarcinoma (a common type of pancreatic cancer) and are patients at the University of Pennsylvania. The goal is to create a large collection of blood samples that researchers can use to study circulating biomarkers (substances in the blood that can indicate disease). This will help us understand pancreatic cancer better and potentially lead to new ways to diagnose or treat it. The study aims to enroll 30 participants, but its current recruitment status is unclear.

Study design
This is an observational study, meaning participants will not receive an experimental treatment. It aims to enroll 30 participants.
What's involved
You would provide about 4 tablespoons of blood within a one-week period, and no more than four times within an eight-week period.
Compensation
Not stated in the trial record.
Follow-up
Your participation would last for an average of one year, or until the study is completed.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05743049

Collection of Circulating Biomarkers in Pancreatic Cancer

Recruiting
Not specifiedAges 18+Observational
Abramson Cancer Center at Penn Medicine
~30 participants
Updated 2026-04-07 on ClinicalTrials.gov
What's tested:Obtaining blood for analysis of various circulating biomarkers

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.
Measured over Through study completion, an average of 1 year
Pancreas Cancer

NCT05743049

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Abramson Cancer Center at University of Pennsylvania

    Philadelphia, Pennsylvaniano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Mark O'Hara, MD · PRINCIPAL_INVESTIGATOR · Abramson Cancer Center, University of Pennsylvania

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma
The subject must be a patient of the University of Pennsylvania
The subject must be able to provide informed consent
The subject must be 18 years of age or older
  • To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use.Through study completion, an average of 1 year